The documents were filtered and summarized for final evaluation. Statistical analysis was performed with Stata 14 software (Stata Corporation, College Station, TX, USA). In this analysis, the incidence of adverse reactions during treatment of influenza was lower in the LHQW group compared to the conventional drug group (RR = 0.74, 95% CI = 0.630.87, p < 0.001). Lianhua Qingwen capsule/granule (LHQW) is obtained by combining Ma Xing Shigan Decoction with Yinqiao Powder and widely used in the clinical treatment of respiratory disorders (Liu et al., 2010). Anti Covid-19 Drugs: Need for More Clinical Evidence and Global Action. Experiments on animals using a combination of LHQW and oseltamivir to treat influenza B virus infections showed a potential inhibitory effect on overexpression of TNF-, MIP-1, RANTES, IFN-, IL-6, IL-8, IP-10, and MCP-1 at the mRNA level, and consequent prevented of the development of severe inflammatory reactions (Yang et al., 2020). Case reports, unrelated studies, those with duplicate data, reviews, commentaries and animal-based studies were excluded from the current meta-analysis. Trim and Fill: a Simple Funnel-Plot-Based Method of Testing and Adjusting for Publication Bias in Meta-Analysis. DerSimonian, R., and Laird, N. (1986). Anal. System-Organ Code Retrieval Involved. Ping F., Li Z., Zhang F., Li D., Han S. Effects of Lianhua Qingwen on pulmonary oxidative lesions induced by fine particulates (PM2.5) in rats. In the Philippines, its Food and Drug Administration approved Lianhua Qingwen on 7 August 2020 as a traditional herbal product that helps remove "heat-toxin invasion of the lungs, including symptoms such as fever, aversion to cold, muscle soreness, stuffy and runny nose". Though the quality of the included literature was mixed, the lung protection effects of LHQW was demonstrated. Before Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional Chinese medicine Lianhua Qingwen. The current meta-analysis was performed to evaluate the safety profile of LHQW in relation to conventional drugs (PROSPERO CRD-42020224180). Received 2020 Jul 3; Revised 2020 Aug 9; Accepted 2020 Aug 16. The post-marketing monitoring data incorporated information on the following gastrointestinal adverse reactions: nausea, diarrhea, vomiting, abdominal pain, abdominal distension, dry mouth; as well as skin rash, itching, dizziness (Yiling Pharmaceutical, 2021). the contents by NLM or the National Institutes of Health. Secondly, separate evaluations were further performed for different diseases and types of adverse reactions. In conclusion, this review has summarized the benefits of LHQW for treating virus infection, especially its anti-SARS-CoV-2 role as an alternative candidate and complementary strategy. Beijing: China Medical Science Press. Lianhua Qingwen(Forsythia suspensa (Thunb.) Shi, M., Peng, B., Li, A., Li, Z., Song, P., Li, J., et al. With gradual improvement of the adverse drug reaction monitoring system of China, reports of adverse reactions or events have increased. J. Pharmacovigilance. Herald. Traditional Chinese medicine Lianhua Qingwen capsule has been proven effective for the treatment of COVID-19, China's top respiratory expert Zhong Nanshan said in a webinar with overseas Chinese students on Monday. Previous studies reported that Lianhua Qingwen might have positive effects, including broad-spectrum antiviral, cough and expectorant, antipyretic and anti-inflammatory, immune-regulating, effective antibacterial and other systemic intervention functions (Liu et al., 2010; Liu 2015; Wang, et al., 2015). Available at: https://mpns.science.kew.org/mpns-portal/(Accessed December 19, 2021). 2015, 731765. doi:10.1155/2015/731765, Jin, L., Xu, Y., and Yuan, H. (2020). 339 (7), b2535. The official monograph of LHQW states that the adverse effects are "unclear". Academician Yiling Wu systematically constructs the theory of collateral disease, provides theoretical guidance for the formulation of Lianhua Qingwen, and gives . As COVID-19 has led to serious death and lacks treatment strategies, the potential therapeutic drugs are increasingly being explored. Clin. Subgroup analysis showed the incidence of dizziness or headache was significantly reduced with LHQW group (RR = 0.54, 95% CI = 0.340.84, p = 0.006), no statistical difference was detected for drowsiness and legacy neuralgia. New Progress in Study on Mechanism of Lianhua Qingwen Capsules for For rheum, sample size could partially explain heterogeneity (p = 0.005), but not year of publication (p = 0.658) and treatment of the control group (p = 0.712). It was found that the total effective rate of LHQW granules combined with abidor treatment (LHQW group) was significantly higher than that of abidor group (80.95 % vs 64.86 %), while the rate of severe illness was markedly lower (14.29 % vs 23.65 %) [44]. Use Overdosage Contraindications Special Precautions Adverse Reactions Storage MIMS Class ATC . Seven studies reporting treatment of chronic obstructive pulmonary disease were included, among which two described adverse reactions. We hope this review will not only present comprehensive evidence for LHQW use in COVID-19 therapy, but also fuel antiviral researches and put forward promising insights for further antiviral drug development. (10), 100. Front. Traditional Chinese medicine Lianhua Qingwen treating corona - PLOS ex DC. Fig. Efficacy and mechanism of Lianhua Qingwen Capsules(LHQW) on chemotaxis of macrophages in acute lung injury (ALI) animal model. In vitro, LHQW capsules could inhibit the proliferation of influenza viruses of various strain with the 50 % inhibitory concentration ranging from 0.35 to 2mg/mL [24]. The collected evidence demonstrated that LHQW exhibited benefits against COVID-19. [Caprifoliaceae; Lonicerae Japonicae Flos], Gypsum Fibrosum, Isatis indigotica Fort. There was no statistically significant difference in the incidence of hepatobiliary system damage between the LHQW group and the conventional drug group (RR = 0.86, 95% CI = 0.581.28, p = 0.461). Most patients infected with the coronavirus are showing mild symptoms, taking Lianhua Qingwen Capsule as early as possible, the effect will be obvious, It [sic] can recover 91.5% of mild cases and . doi:10.13422/j.cnki.syfjx.20201099, Ye, C., Gao, M., Lin, W., Yu, K., Li, P., and Chen, G. (2020). [9], During the COVID-19 pandemic, the government of the People's Republic of China (PRC) approved the use of Lianhua Qingwen for mild to moderate COVID-19 cases in January 2020, and promotes the use of the medicine abroad. (Lianqiao), Lonicera japonica Thunb. FOIA Compared with oseltamivir, LHQW achieved a similar therapeutic effectiveness with reduction of the duration of illness and duration of influenza A virus H1N1 shedding [36]. J. Eval. doi:10.1016/j.jep.2013.12.022. Hu K., Guan W.J., Bi Y., Zhang W., Li L., Zhang B., Liu Q., Song Y., Li X., Duan Z., Zheng Q., Yang Z., Liang J., Han M., Ruan L., Wu C., Zhang Y., Jia Z.H., Zhong N.S. Expert: Lianhua Qingwen capsule proven effective for COVID-19 - CGTN Immune imbalance mechanism and intervention strategy in patients with coronavirus disease 2019 (COVID-19). Since the adverse reactions of LHQW are relatively minor, these functional changes can be recovered. Please be informed that only the Lianhua . Comprehensive analysis of influenza may provide a significant advantage in generalization of the conclusions. Research progress in use of traditional Chinese medicine for treatment of spinal cord injury. The documents were filtered and summarized for final evaluation. Available at: http://m.news.cctv.com/2020/03/17/ARTIEYQ2aws8fPYWQxjnynzo200317.shtml?from=singlemessage (Accessed Apirl 29, 2021). Wang L., Yang Z.H., Zhang H.R., Yu H.X., Yang K., Fu B.H., Yang H.T. Lianhua Qingwen is a commonly used Chinese patent medicine to treat viral infection. Similar results were obtained in subgroup analysis of hepatic function abnormal and transaminase increased. A recent clinical trial including 36 common cold with wind-heat syndrome patients demonstrated that LHQW (three times daily for four days) treatment could significantly reduce TCM symptom score, with the median time to fever relief of (45) h and the median time to fever clearance of 36h [35]. Since the outbreak of COVID-19, Lianhua Qingwen Capsules have been recommended by the official Chinese "Diagnosis and Treatment Protocol for COVID-19" and widely used in designated admission hospitals for COVID-19. COVID-19: TCM Lianhua Qingwen speeds up recovery but no effect in Both Lian-Hua-Qing-Wen Capsule (LHQWC) and Jin-Hua-Qing . The Cochrane Collaboration risk of bias tool comprising seven items was applied to assess the risk of bias of each eligible study (Higgins et al., 2011). LHQW group has a reduced incidence of respiratory system damage compared to the conventional drug group (RR = 0.46, 95% CI = 0.290.74, p = 0.001). However, no statistical difference was detected with regard to rash (RR = 0.60, 95% CI = 0.211.67) and dizziness (RR = 1.79, 95% CI = 0.339.74). Ma Y., Zhang Z., Wei L., He S., Deng X., Ji A., Zhou B., Jiang D., Li M., Wang Y. Efficacy and safety of Reduqing granules in the treatment of common cold with wind-heat syndrome: a randomized, double-blind, double-dummy, positive-controlled trial. Lianhua Qingwen capsules have been proven to speed up symptoms recovery but no effect in preventing infections from worsening. The research data were obtained from the academic databases (up to August 8, 2020) including Pubmed, CNKI and Web of Science, on ethnobotany and ethno medicines. Common side effects are heart palpitations, nausea, and vomiting. There was no statistically significant difference in the incidence of adverse reactions during treatment of rheum between the LHQW group and the conventional drug group (RR = 0.46, 95% CI = 0.121.83, p = 0.270). The https:// ensures that you are connecting to the doi:10.14009/j.issn.1672-2124.2013.08.001, Wang, Y. Progress on the efficacy and clinical application of Lianhua Qingwen capsule (LHQW). Further long-term high-quality studies are essential to validate our conclusions. Our findings support the adverse reactions recorded by Yiling Pharmaceutical, and compare the incidence risk of gastrointestinal system damage and rash with the control group. 66 (6), 771777. Literature Analysis of Clinical Application and Adverse Drug Reaction/Event of Lianhua Qingwen Capsule. Yiling Pharmaceutical (2021). (2020). Dr. Tan says that LianHua QingWen is not advisable for COVID patients who are experiencing a chilling sensation due to the infection. Nevertheless, none of the in vivo studies are directly focused on Corona virus or COVID-19. showed that the usual treatment in combination with LHQW capsules (4 capsules thrice daily for 14 days) had significantly higher recovery rate, and shorter median time to symptom recovery, as compared with control group [43]. Trials. Broad Anti-viral Capacities of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-gan Granule and Rational Use against Covid-19 Based on Literature Mining. The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author. 8600 Rockville Pike Keywords: Lianhua Qingwen capsule; Meta-analysis; influenza; systematic review. (japanese honeysuckle) flower 27.41 mg, gypsu . Mo H.Y., Yang Z.F., Zheng J.P., Mo Z.Y., Li Y.M., Xiao Z.L. Subgroup, sensitivity and meta-regression analyses were conducted to determine the potential sources of heterogeneity. Second, the herbs in LHQW are mostly grown in specific areas, the varied origin of herbs are usually together with different content of bioactive ingredients, thus the quality standard control of the included crude drugs should be encouraged [12]. Dong L., Xia J.W., Gong Y., Chen Z., Yang H.H., Zhang J., He J., Chen X.D. The incidence of adverse reactions during treatment of influenza A (H1N1) was lower in the LHQW group compared to the conventional drug group (RR = 0.21, 95% CI = 0.130.36, p < 0.001). Lv R.B., Wang W.J., Li X. 3.2.2. Therefore, we conducted a systematic review of the . The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Available at: http://www.plantsoftheworldonline.org (Accessed December 18, 2021). The serious attack of Coronavirus Disease 2019 (COVID-19), infected by Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (SARS-CoV-2), has quickly spread around the globe [[1], [2], [3]]. Firstly, to our knowledge, this meta-analysis provides the most comprehensive evaluation of the clinical safety of LHQW. (Hongjingtian), Mentha haplocalyx Briq. Five studies reported respiratory system damage as an adverse event. (Nat. Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review. Drug Discov. Drug Related Hospital Admissions: the Role of Definitions and Intensity of Data Collection, and the Possibility of Prevention. 46 (5), 395400. (2002). Reports emerged indicating that this process consumed significant logistical capacity, drawing criticism about misuse of resources at a time when people were struggling with shortages of basic needs such as food and medication. Yang C., Wang Y., He J., Yan W., Jiang H., Chen Q., Li L., Yang Z. Lianhua-Qingwen displays antiviral and anti-inflammatory activity and synergistic effects with oseltamivir against influenza B virus infection in the mouse model. Alternat Med. This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of COVID-19. 228 (2), 8390. Vahl [Oleaceae; Forsythiae Fructus], Lonicera japonica Thunb. For thousands of years, traditional Chinese medicine (TCM) plays an important role in treating human diseases [[9], [10], [11], [12], [13], [14]]. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Skin rashes, allergic dermatitis and other skin allergic reactions are also reported to be associated with LHQW treatment, and may be related to Houttuynia cordata Thunb. The China National Medical Products Administration agency has officially approved LHQW for the treatment of mild or ordinary COVID-19 pneumonia (Ahsan et al., 2020; Cao et al., 2020; Chan et al., 2020; Khan et al., 2020; Kupferschmidt and Cohen, 2020). [8], Lianhua Qingwen has also been promoted and distributed by the government in Hong Kong (HK). 56 (2), 455463. Wu et al. [Efficacy and safety of Lianhua Qingwen capsule for influenza a Finally, 217 experimental studies on the Chinese population were included for study featuring 1759 cases of adverse reactions following clinical treatment (publication years ranging from 2005 to 2021). There was no statistically significant difference in the incidence of adverse reactions during treatment of other diseases between the LHQW group and the conventional drug group (RR = 0.95, 95% CI = 0.651.39, p = 0.780).